Notably, upregulation in these patients was largely restricted to A2AR, 2B4, and CCL17, suggesting the potential involvement of alternative pathways in regulating CD4+ T cell function within siglec-7 high breast tumor microenvironment. This evidence concerns the gene ADORA2A and breast neoplasm.